Study of Lipoprotein-Associated Phospholipase A2 as a Potential Biomarker for Diabetic Kidney Disease in Type 2 Diabetes

Salem, Ibrahim M.; Ismail, Mabrouk I.; Ghorab, Adel A.M.; Fouad, Rabab; Mosbah, Osama; Khalifa, Ghada; Ibraheem, Alaa Ahmed Abdelateef; Mahmoud, Medhat Ibrahim; Kamal, Nafesa M.

doi:10.21608/ejhm.2022.254086

Study of Lipoprotein-Associated Phospholipase A2 as a Potential Biomarker for Diabetic Kidney Disease in Type 2 Diabetes

Document Type : Original Article

Authors

10.21608/ejhm.2022.254086

Abstract

Background: A common consequence of diabetes is diabetic kidney disease (DKD). Increased Lp-PLA2 plasma levels have been related to higher risk of development of DKD in type 2 diabetes patients.
Objective: To illustrate the significance of using lipoprotein phospholipase A2 as potential early biomarker for detecting diabetic nephropathy among type 2 diabetic patients.
Patients and methods: A case-control study were conducted at the nephrology unit in partnership with Theodor Bilharz Research Institute and the Internal Medicine Department of Zagazig University Hospitals. This study was performed on (33) type 2 diabetic patients and were compared with 11 healthy subjects who were matched age, sex as a control group. Plasma LP-PLA2 was assessed among all subjects.
Results: It is more common in diabetic patients to have elevated plasma LP-PLA2 levels than in healthy people. LP-PLA2 levels were much higher in diabetic patients with microalbuminuria than in those with normoalbuminuria, and higher with macroalbuminuria than with microalbuminuria. Plasma LP-PLA2 levels were correlated to creatinine, urea and UACR reflecting that it is a marker of early nephropathy. The ROC curve for the validity of plasma LP-PLA2 in detecting kidney disease in type2 diabetic patients with micro and macroalbuminuria showed high specificity and sensitivity.
Conclusion: LP-PLA2 could be considered an early indicator of diabetic nephropathy in patients with type 2 diabetes.

Keywords